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plaints.  Conclusion: Anthropometric parameters and QoL 
improved during the observational period in this HPN co-
hort. These Swiss HPN data are prerequisite for evaluation 
and comparison of HPN recommendations and best clinical 
practice, status of professional care instructions related to 
HPN effectiveness, quality of treatment and patient safety. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Parenteral nutrition (PN) is life saving and indicated 
when the gut is not functioning and due to oral or enter-
al intake not being sufficient to reach appropriate re-
quirement target. Advances in home parenteral nutrition 
(HPN) enable many patients to survive, to live at home 
and to have good or reasonably good quality of life (QoL) 
in their normal environment instead of prolonged hospi-
tal stays. Today it represents an established and common-
ly used procedure  [1] . Even in elderly patients with can-
cer, HPN has been shown to benefit nutritional status and 
QoL  [2] . Patients can be treated in an outpatient setting, 
resulting in reduced healthcare costs  [3] .
 Since the introduction of HPN in the 1970s, HPN 
prevalence and incidence have been steadily increasing in 
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 Abstract 
 Background: There are no specific Swiss home parenteral 
nutrition (HPN) data showing patient characteristics, quality 
of life (QoL) and complications. The goal of this study was to 
collect representative nationwide data on current adult HPN 
patients in Switzerland for international comparability and 
benchmarking.  Methods: This was a multicenter, nation-
wide, observational study. We conducted interviews for de-
mographics, PN characteristics, QoL and complications. The 
data were assessed at baseline and after a follow-up of 
3 months using a questionnaire.  Results: Thirty-three adult 
patients were included. The most common underlying dis-
eases were cancer, radiation enteritis and state after bariatric 
surgery, and the most prevalent indication was short bowel 
syndrome. During the 3-month observation period, signifi-
cant increase or stabilization of body weight occurred in the 
patients, physical activity scores improved from 34.0 to 39.4 
and mental scores improved from 41.9 to 46.4. HPN depen-
dency and traveling restrictions were of the greatest con-
cern. Diarrhea, xerostomia and/or thirst were frequent com-
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Europe, with a large multicentric survey showing an an-
nual incidence of 4–6 per 10 6 inhabitants and a preva-
lence of 2–40 per 10 6 inhabitants  [4–6] . The most com-
mon indications for long-term HPN in Europe are 
Crohn’s disease, mesenteric vascular disease, cancer and 
radiation enteritis  [7] . Other more recent studies confirm 
that malignancy is the single most common indication for 
HPN  [8, 9] .
 PN causes important restrictions in personal life, par-
ticularly, in social life, mainly due to the cyclic noctur-
nal HPN administration. These patients show reduced 
QoL, with physical problems, HPN dependency, social 
restrictions, sleeping problems and financial problems 
 [10] .
 Shaw et al.  [8] performed a first retrospective epide-
miological analysis of patients with home artificial nutri-
tion in Switzerland, based on data provided by the leading 
national insurance provider. Over the 5-year analysis pe-
riod, from 2005 to 2009, 433 HPN patients were recorded, 
showing increasing frequency of HPN.
 Data on HPN patients’ characteristics and living con-
ditions are scarce, and little is known about the challeng-
es and problems these patients face. The goal of this pro-
spective study was to collect representative nationwide 
data on the current Swiss adult HPN patient group for 
international comparability and benchmarking.
 Material and Methods 
 Study Design and Patient Selection 
 This multicenter, nationwide, observational study started in 
April 2013 and ended in March 2014. General practitioners and 
hospital physicians taking care of HPN patients were contacted. 
Their names were accessible through the Swiss Association for 
Common Tasks of Health Insurers (SVK). The physicians ad-
dressed were requested to obtain written consent from their pa-
tients to participate in the study. Inclusion criteria were the follow-
ing: age >18 years, receiving HPN, life expectancy >30 days and 
signed written consent. Patients fulfilling the inclusion criteria 
were either visited at home for an interview or interviewed in their 
hospital’s outpatient clinic.
 Data Collection 
 Data were collected using an entry questionnaire and a follow-
up questionnaire 3 months later. Patients included in the study 
either filled out the questionnaire together with their interviewer 
or on their own. The mean interview duration was about 45 min. 
The following data were collected: personal and demographic data, 
social aspects, detailed nutrition regimes and QoL according to the 
validated Short Form 36 Health Survey version 2 (SF-36v2) TM 
questionnaire, anthropometric data over time, indications for PN, 
medical history and prevalence of complications. The documents 
were available in three languages: German, French and Italian.
 Body mass index (BMI) was calculated as weight in kilograms 
divided by height in meters squared (kg/m 2 ). To assess the effects 
of HPN on personal life, behavior and emotions, patients were in-
terviewed about the effects of HPN and asked to check all appli-
cable responses. HPN-related complaints could be evaluated by 
the patients in the questionnaire by choosing from 3 options: ‘a 
little’, ‘medium’ or ‘strong’. To assess physical performance and 
mental health status at different time points (before disease, just 
before starting HPN and during HPN), the patients could choose 
between 4 different options (‘very good’, ‘good’, ‘bad’ and ‘very 
bad’). The QoL of the patients on HPN was assessed using the SF-
36v2 TM  questionnaire at the time of entry in the study and at the 
time point when the patients had to answer the follow-up ques-
tionnaires.
 The SF-36v2 TM is a multipurpose health survey with 36 ques-
tions. It yields an 8-scale profile of functional health and well-
being scores as well as psychometrically based physical and men-
tal health summary measures and a preference-based health util-
ity index  [11] . These 8 scales are reduced to a physical component 
summary (PCS = physical functioning + physical role + bodily 
pain + general health) and to a mental component summary 
(MCS = vitality + social functioning + emotional role + mental 
health)  [12] .
 Statistical Analysis 
 The statistical assessment was performed with IBM SPSS sta-
tistics for Windows, version 19.0 (IBM Corp., Released 2010, 
 Armonk, N.Y., USA). The Wilcoxon test was used for continuous, 
non-parametric data. Results are reported as means with SD or as 
numbers and percentages. A p value of <0.05 was considered sta-
tistically significant.
 Ethical Approval 
 This study was conducted in accordance with the ethical guide-
lines of the 1957 Declaration of Helsinki, and written informed 
consent was obtained from all participants. Ethical approval for 
the study was obtained from the Bernese Cantonal Ethics commit-
tee (KEK Bern, study no. 068/13), Bern, Switzerland.
 Results 
 Forty-one patients were recorded during the 1-year in-
vestigation ( fig. 1 ). Eight of the patients who were com-
parable to the study population did not consent to par-
ticipate, while 33 participated (n = 100%) and filled in the 
entry questionnaire. The follow-up questionnaire was 
filled in by 24 patients. In 3 patients, the loss of follow-up 
was because they died during the study period due to the 
underlying disease (cancer), 4 patients ceased HPN and 
2 patients had no more interest in the further participa-
tion of the study. This corresponds to about 4 patients per 
1 million inhabitants in Switzerland and is comparable 
with other European countries. All tertiary university 
hospitals and all important referral centers of different 
regions of Switzerland, as well as namely physicians, who 
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are familiar with HPN therapies, were contacted but not 
all of them had patients to contribute. The patients’ char-
acteristics are listed in  table 1 . The mean age on starting 
HPN was 53.8 ± 17.8 years. At the time of the initial in-
terview, HPN treatment had been initiated on an average 
of 3.44 years previously, with a wide range from 2 days to 
30.75 years. The mean BMI before disease was 28.5 ± 11.4 
kg/m 2 and decreased significantly before starting HPN to 
a BMI value of 19.6 ± 6.7 kg/m 2 (p < 0.001). At the time 
point of the first interview, the mean BMI had increased 
significantly with HPN treatment to 22.0 ± 6.1 kg/m 2 (p < 
0.001). The BMI could be kept stable at 21.5 ± 3.2 until 
the follow-up interview ( fig. 2 ).
 Underlying Diseases and Indications for HPN 
 The underlying diseases and the indications for HPN 
of the 33 patients are reported in  table 2 . As underlying 
disease cancer was predominant (n = 14, 42%), followed 
by post-bariatric surgery and post-radiation enteritis (n = 
4 each, 12%). In 13 (39%) of the cases, a short bowel syn-
drome (SBS) was the indication for HPN.
 Central Venous Catheter-Related Complications 
 Most patients (n = 32, 97%) used tunneled catheter 
systems like the Hickman or the Port-a-cath. Only 1 pa-
tient was fed through a dialysis arteriovenous fistula. In 
45% of the patients (n = 15), there was at least one central 
venous catheter (CVC) replacement during the nutri-
tional treatment, primarily due to infections, CVC occlu-
sions or displacement. Eleven patients (33%) reported at 
least one infection during the HPN period. Intervention-
related CVC complications (e.g. arterial lesions, fixation 
problems) occurred in 5 patients (15%) and CVC occlu-
sions in 5 patients (15%). During the present observa-
tional period (follow-up questionnaire after 3 months 
from baseline), 6 patients (18%) had to have the CVC re-
placed due to infectious complications.
 Effects of HPN on QoL 
 Regarding the employment, 85% (n = 28) of the HPN 
patients were no longer employed, either because of phys-
ical impairment or because they had already retired (n = 
13). Nine percent (n = 3) had an employment with me-
dium physical activity or were students. Less than half of 
the patients (39%, n = 13) were able to do the housekeep-
ing themselves; 58% (n = 19) were dependent on family 
help. Personal care was performed themselves by 88% 
(n = 29). For attaching and removing the PN, 76% (n = 
25) relied on external help, such as a homecare service or 
a nurse.
Table 1.  Patient characteristics
Data Results
Patients, gender, n (%)
Male 12 (36)
Female 21 (64)
Age at start of HPN, years
Age, mean ± SD 53.76±17.75
Age, median 59
Age, n (%), (f:m)
<40 8 (24), (5:3)
41–60 11 (33), (9:2)
61–70 10 (30), (5:5)
≥71 4 (12), (2:2)
Geographical distribution (Switzerland), n (%)
East part 1 (3)
North part 2 (6)
South part 3 (9)
Central part 5 (15)
West part 10 (30)
Region of Berne 12 (36)
Marital status
Married 15 (45)
Single 9 (27)
Divorced 7 (21)
Widowed 2 (6)
Living situation, n (%)
Partner 15 (45)
With children <18 years or with the parents 3 (9)
Alone 8 (24)
Nursing home 4 (12)
Catheter types, n (%)
Hickman 18 (55)
Port-a-cath 14 (42)
Dialysis fistula 1 (3)
All patients
n = 41
Excluded patients
n = 8, consent not given
Included patients
n = 33
Loss of follow-up
n = 3, death
n = 4, ceased HPN
n = 2, withdrawal from study
Follow-up (3 months)
n = 24
 Fig. 1. Study flow diagram. 
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 Performance level and mental health status are shown 
in  figure 3 . Before the disease, 52% (n = 17) of patients 
were very active. During the disease, but just before be-
ginning HPN, 58% (n = 19) were not active at all. This 
improved during treatment with HPN, with 52% (n = 17) 
of patients reporting they were a little active. The mental 
health status was rated very bad in 30% (n = 10) during 
the disease, just before starting HPN. During HPN treat-
ment, only 3% (n = 1) described their mental status as 
very bad. Almost all patients showed improved physical 
and mental QoL after 3 months (PCS 34.02 vs. 39.37; 
MCS 41.91 vs. 46.35), as shown in  figure 4 . Only 2 patients 
(6%) considered themselves healthy, while 7 (21%) de-
scribed themselves as fairly healthy. Most patients report-
ed in the QoL questionnaire that their health was not ex-
cellent at all (n = 12, 36%).
 Aspects of HPN treatment that were reported as most 
disturbing were the restricted ability to travel and the im-
possibility to participate in social events (n = 21, 64%) and 
the dependency on the treatment (n = 19, 58%). Sleep 
Table 2.  Underlying diseases and indication for HPN
Diagnosis n (%)
Cancer 14 (42)
Complications of surgery 5 (15)
Post-bariatric 4 (12)
Others 1 (3)
Radiation enteritis 4 (12)
Crohn’s disease 3 (9)
Systemic sclerosis 2 (6)
Congenital bowel disease (Hirschsprung disease) 1 (3)
Motility disorders 1 (3)
Caecum perforation 1 (3)
Mesenteric infarction 1 (3)
Glycogenosis type Ia (–> severe inappetence) 1 (3)
Indication for HPN n (%)
SBS 13 (37)
Malabsorption 10 (29)
Fistula 4 (11)
Obstruction 3 (9)
Severe malnutrition prior to surgery 1 (3)
Other 4 (11)
15
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disturbances because of noise generated by the mechani-
cal infusion pump were mentioned 8 times (n = 8, 24%). 
Fear of further health complications (n = 5, 15%) and 
problems in partnership/family life (n = 3, 9%) were also 
listed. The HPN-related complaints are shown in the  fig-
ure 5 . The complaint cited most often was by far fatigue 
(n = 31, 94%). Rarely occurring complaints were pains, 
spasms, difficulty in controlling blood sugar level, night 
sweats and post-prandial health problems.
 Discussion 
 The present prospective study is the first detailed anal-
ysis of HPN patients in Switzerland. We consider this sur-
vey as representative for the population of HPN patients 
in our country. Of the 41 HPN patients identified, 33 were 
included. The University Hospital of Berne provided 36% 
of the recruited patients, far more than any other site, 
which may be due to the long lasting clinical experience 
with this population. HPN is prescribed not only by im-
portant referral centers, but also by general practitioners 
taking care of these patients. There are no regular follow-
ups, aspects or guidelines for HPN prescriptions and care 
in Switzerland.
 The age and gender distribution in our study are com-
parable to those of other surveys, which also showed a 
much higher rate of female HPN patients  [4, 13–15] . This 
is influenced by the underlying diseases, for example, 
post-radiation enteritis occurring in patients with gyne-
cological malignancies. SBS may also be more likely to 
occur in women due to the shorter length of their small 
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 Fig. 5. HPN-related complaints. 
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intestine  [16] . A final reason is the increasing number of 
bariatric patients in Switzerland, of which 75% are wom-
en  [17] .
 Compared to other studies, the mean duration of HPN 
in our cohort is slightly lower (mean 3.44 years), but with 
a broader range (0.1–31 years)  [10, 18] . There was also 
greater variation in our study due to the inclusion of a 
patient with Hirschsprung disease requiring HPN since 
birth and due to the inclusion of a patient with SBS since 
more than 30 years, corresponding to almost 9 times the 
mean duration of HPN.
 Approximately, half of our patients have had at least 
one CVC replacement during HPN treatment. The com-
plication mentioned most often was CVC infection. 
This corresponds with the results of previous studies: 
28.6% had at least one catheter sepsis and 50% had at 
least one catheter change. CVC infection rate ranged be-
tween 0.38 and 4.58 episodes per 1,000 catheter days  [19, 
20] . To prevent infections and other catheter-related 
complications, good clinical practice and an experi-
enced multidisciplinary team are mandatory  [21] . Six 
patients (18%) needed a catheter replacement because of 
infectious complications in the 3 months of follow-up. 
This rate has to be interpreted with caution, because of 
the short follow-up period and because many patients 
just had started with the HPN therapy. The procedure 
in case of suspected CVC-related infection and subse-
quent removal is managed in a similar way throughout 
Switzerland. When a catheter infection is suspected, pe-
ripheral blood culture samples and culture samples from 
each catheter lumen are taken. If there is a definitive sign 
of local infection, for example, purulent secretion at the 
exit site, or a catheter-induced sepsis, the CVC is re-
moved immediately and an antibiotic therapy is started 
 [22] .
 In a European multicenter study, Van Gossum et al. 
 [4] showed almost the same distribution of underlying 
diseases (cancer 42%, Crohn’s disease 15%, vascular dis-
eases 13%). Recently, the ESPEN HPN-Chronic Intesti-
nal Failure Special Interest Group (European Society of 
Clinical Nutrition and Metabolism) created a survey to 
describe the use of HPN in post-bariatric surgery, includ-
ing the indications and outcome. An interesting finding 
in our study is that 4 patients (nearly 15%) of our study 
population need HPN after bariatric surgery. Patients un-
dergoing malabsorptive procedures are at risk of develop-
ing nutritional deficiencies and protein-energy malnutri-
tion (PEM). A small number of patients will develop PEM 
and will therefore require HPN months to years after bar-
iatric surgery. Bariatric surgery has increased significant-
ly in the last years in Switzerland, with 750 bariatric inter-
ventions in 2001 compared with 4,000 in 2013  [17] . Not 
much is known about this group of patients requiring 
HPN to compensate for complications or side effects after 
bariatric surgery  [23, 24] . Given the proportion of mor-
bidly obese people in the Swiss population (in 2012: 11% 
men and 9% women)  [25] , post-bariatric PEM will be an 
emerging problem in the future.
 On the other hand, other indications have dramati-
cally decreased, noticeably, the 4% proportion of AIDS 
patients in earlier years, most of who died of wasting 
syndromes due to the lack of effective therapies  [4, 26] . 
New treatments, better outcome and prevention strate-
gies have increased survival and decreased the need for 
HPN in such patients  [27] . This was also reflected in the 
fact that there were no AIDS patients in the cur-
rent study. In the study of Van Gossum et al.  [4] , cancer 
was in first place (39%) at almost the same rate like in 
our survey. The proportion of HPN patients with onco-
logical tumors has increased over the past years in 
 Europe  [28] . Previous Swiss data about the indications 
for home artificial nutrition demonstrated that neo-
plasms were the most frequent underlying disease (51%), 
diseases of the digestive system on the second place 
(10.4%) and diseases of the nervous system in third 
place (9.6%)  [8] . In our study, there were no patients 
with underlying neurological disorders. This is probably 
due to the fact that patients with neurological disorders 
can mostly be treated with enteral nutrition, including 
PEG  [29] . Another important fact is the change in offi-
cial recommendations for HPN over the last years, re-
positioning HPN as a palliative treatment in cancer pa-
tients because of the relatively small proportion of PN-
associated comorbidity risk factors  [14, 30] . Regarding 
the indications for HPN, we found that SBS is the most 
frequent indication (37%), consistent with other pub-
lished data  [31, 32] .
 Our investigation also focused on the QoL of HPN pa-
tients. Both physical and mental QoL, assessed by the 
non–disease-specific SF-36v2, improved over time in our 
patients. Many other studies determined the QoL using 
the Karnofsky score, the SF-36 or a new specific question-
naire for HPN patients. Overall, patients with HPN have 
poorer QoL than healthy people or patients with chronic 
illnesses  [13, 19, 32–34] . An earlier study with only 13 
participants showed that none of those HPN patients had 
a regular employment, but 46% did most of the house-
keeping  [35] . Our data showed that 85% of patients had 
no employment, and only 39% were able to do the house-
keeping on their own.
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 The additional subjective definition of physical perfor-
mance and mental health status were also investigated by 
Winkler et al.  [36] , who achieved greater insight into the 
lives of HPN patients and their definition of QoL. In our 
study, most of the patients reported that they were ‘very 
active’ or ‘active’ before disease, comparable with healthy 
individuals. In the immediate period before starting 
HPN, most of the patients felt very tired, adynamic and 
‘not active’. Fortunately, after initiation of HPN, the per-
formance level increased after weeks in most patients, 
showing the positive effects of HPN on well-being, body 
function and performance levels. The results concerning 
mental health were similar, with ‘poor’ mental health re-
ported before starting HPN and ‘good’ mental health af-
ter initiation of HPN.
 We conclude that our population profits by HPN from 
a better health status. Other studies confirm our findings 
showing improved QoL with HPN in both patients with 
benign and malignant underlying disease  [37–39] .
 Restricted travel options, limited social interaction 
and activities as well as loss of independence were the 
most frequent complaints related to HPN. Other studies 
showed similar results, mostly evaluated in surveys: the 
lack of freedom, being dependent and limitations in so-
cial life  [40, 41] . Moreover, Huisman-de Waal et al.  [42] 
showed social and somatic impacts of HPN therapy on 
daily life, which are comparable with our data (e.g. fa-
tigue, xerostomia, diarrhea;  fig. 5 ).
 Strengths and Limitations of the Study 
 This prospective study provides the first detailed 
analysis of HPN patients in Switzerland. It is intended 
to regularly follow-up (in longer time periods) this co-
hort. The presented data will form the basis for a na-
tional HPN registry, which is needed to evaluate the spe-
cific situation of this cohort in the national (healthcare) 
context.
 The fact that the follow-up of the study was only 
3 months, and 3 patients had just started HPN before in-
clusion in the study is a limitation. The short duration was 
chosen to minimize patients lost to follow-up. Second, it 
was difficult for most patients during the survey to distin-
guish between HPN-related side effects and side effects 
due to underlying disease, and it was very challenging to 
determine whether improved or worsened QoL was 
caused by the underlying disease or is a direct conse-
quence of the HPN. A disadvantage of our study is that 
we do not have the information about how many patients 
were eligible for the present study, but did not give their 
consent to the physicians in charge.
 Conclusion 
 We conclude that PN is life saving and shows physical 
and mental benefit for HPN patients, but there are also 
negative implications for QoL, especially in terms of so-
cial and emotional aspects and loss of autonomy. The 
number of patients after bariatric surgery seems to in-
crease steadily, and PN is effective in this population. This 
first prospective analysis of Swiss HPN patients, focusing 
on anthropometric parameters and QoL, shows major 
improvements over the 3 months study period. These pa-
tients should be monitored over the long term to evaluate 
and compare outcomes and the impact of HPN on the 
underlying disease and HPN-associated complications. A 
national registry is a prerequisite for international com-
parability and benchmarking and can help to improve 
treatment quality and safety as well as to define best prac-
tices of HPN.
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